Converting from a Spray-Dried Dispersion to a KinetiSol Formulation in <5 Months

A Phase 2 oral drug candidate formulated as a spray-dried dispersion faced limitations in bioavailability, pill burden, and solvent-intensive manufacturing. In less than five months, AustinPx converted the program to a KinetiSol™ formulation, achieving a 5x increase in AUC, reducing manufacturing time by 67%, and eliminating organic solvents and secondary processing steps. The result was improved in vivo performance, lower cost of goods, and a scalable path forward to Phase 3.